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They assert that the thrombin clotting time (TCT) and activated partial thromboplastin time (aPTT) are qualitative measures of dabigatran activity, while the ecarin clotting time (ECT) and dilute TCT are quantitative. As indicated in our article, we agree. The value of both the TCT and aPTT is that they are widely available, rapidly reported, and normal results indicate that dabigatran is not exhibiting a significant anticoagulant effect. The ECT is not widely available in the United States, and the results of the dilute TCT is often not reported for at least 24 hours. We also agree that determining the timing of the last dose of dabigatran and current renal function is vitally important to understanding the overall degree of dabigatraninduced coagulopathy. This is discussed in detail in our article.
The correspondents mention a very exciting investigational therapy, idarucizumab, which the authors are currently investigating in the RAADIANT trial. The preclinical and phase I clinical trial data are promising. [1] [2] [3] One particular piece of data mentioned in the study by Grottke et al is especially intriguing in the context of the patients we discussed in our article. Grottke and colleagues report that ex vivo administration of a 30-mg/kg dose of idarucizumab completely neutralized dabigatran, even at concentrations of 1500 ng/mL. 2 The highest level of dabigatran measured in our patients was 1200 ng/mL. 4 Glund et al has reported that doses up to 8 g of idarucizumab is safe and well tolerated. 3 Based on the patient's dosing weight, 3.2 g of idarucizumab would have constituted a 30-mg/kg dose, which is within the dosing range described as being ''safe and well tolerated.'' 3 Obviously, idarucizumab is not currently available for clinical use during the period of time analyzed in our analysis and is presently only available to participants of the RAADIANT study. Therefore, the statement that there was no specific antidote for dabigatran reversal was a correct statement and remains true today. We believe that idarucizumab has the potential to revolutionize the management of dabigatran-associated hemorrhage, and we eagerly await the results of the RAADIANT trial.
Pollack et al correctly point out that the data supporting a beneficial effect from the use of recombinant factor VIIa, fresh frozen plasma (FFP), and prothrombin complex concentrate (PCC) in dabigatran-associated hemorrhage is not definitive. Our interpretation of the current literature which consists predominately of case reports and ex vivo studies is that the degree of benefit is unclear and often contradictory between studies. Our retrospective analysis is inconclusive about the value of any repletion or reversal strategy (factor VIIa, FFP, or PCC), and we make no recommendations for or against any of these therapies.
We completely agree with the statement that ''despite logistical challenges, hemodialysis is an effective method for reducing plasma concentrations of dabigatran.'' That is clearly demonstrated by our work. Until an ideal reversal agent is available, hemodialysis is the only effective way to remove dabigatran from the intravascular space.
We also agree with the 6-step management strategy outlined by Pollack et al. It is virtually identical to the strategy we discuss in our article and presently use in our institution. Besides the conclusion that hemodialysis is effective for removing dabigatran, another important finding from our analysis is the presence of a dabigatran ''rebound effect.'' 4, 5 We strongly recommend that serial measurements of aPTT, TCT, and dabigatran levels be done during and after cessation of hemodialysis. Prolongation of these tests should raise concerns for increasing dabigatran levels that have redistributed from the extravascular space. In our experience, restarting hemodialysis is the appropriate clinical response in this setting. Interestingly, Schiele et al observe a reemergence of the anticoagulant effect of dabigatran in their rat continuous infusion model *25 minutes after administration of idarucizumab.
1 This is secondary to the complete saturation of idarucizumab. Therefore, even after idarucizumab administration, clinicians may be wise to follow serial measurements of aPTT and TCT to monitor for idarucizumab saturation secondary to extravascular mobilization of dabigatran.
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